European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

Europe's most promising oncology biotechs and other key stakeholders will gather in Oslo, Norway, September 15-17 for the 2^nd European Cancer Cluster Meeting (ECCP 2010). Co-hosted by the Oslo Cancer Cluster and the Cancer-Bio-Santé Cluster from Toulouse, the two-day meeting is a unique partnering opportunity for oncology biotech companies, business development and licensing executives from the pharmaceutical industry and investors, as well as innovative researchers and clinicians.

“Treatment and survival rates for cancer continue to improve and we believe ECCP provides the perfect forum for the oncology community to meet and find ways to further accelerate the development and uptake of new diagnostics and treatments.”

The programme features seven compact sessions during the two-day conference with "Oncology 2020" as the theme for two opening sessions and five core sessions addressing important aspects of oncology research and development, business development and investor relations with partnering as the overall theme.

Chaired by Dr. Richard Gallagher from Hopeful Monster Publishing, and former editor of The Scientist, the high quality speaker line-up includes:

• Prof. Jonathan Knowles, Inst. for Molecular Medicine Finland & Ecole Polytechnique Federale de Lausanne
• Doug Ulman, President & CEO of the Lance Armstrong Foundation
• Prof. Olli Kallioniemi, Director, Institute for Molecular Medicine Finland
• Dr. Ginette Serrero, CEO, A&G Pharmaceutical, Inc.
• Dr. Chris Sheldon, Business Development Manager, Astra Zeneca
• Dr Phil L'Huillier, Director of Business Management, CRT

A roundtable will discuss how a "global bioscience gateway" involving partners from the US, Europe and China can accelerate the development of new cancer diagnostics and medicines.

In addition, meeting sessions will address important aspects of oncology including the role of biomarkers in personalised medicine, the need for cancer-focussed clinical trial networks and ways to adapt to the financing/partnering climate.

Bjarte Reve, CEO of the Oslo Cancer Cluster aims to build on the success of last year's inaugural conference which attracted some 263 companies from 23 countries: "Treatment and survival rates for cancer continue to improve and we believe ECCP provides the perfect forum for the oncology community to meet and find ways to further accelerate the development and uptake of new diagnostics and treatments."

Find the programme at www.ECCP2010.com